Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
, 99 (2), e18723

Health-related Quality of Life and Costs of Switching Originator Infliximab to Biosimilar One in Treatment of Inflammatory Bowel Disease

Affiliations
Observational Study

Health-related Quality of Life and Costs of Switching Originator Infliximab to Biosimilar One in Treatment of Inflammatory Bowel Disease

Saara Huoponen et al. Medicine (Baltimore).

Abstract

Effectiveness, efficacy and safety of biosimilar infliximab (CT-P13) in inflammatory bowel disease (IBD) patients has been shown in previous studies. Limited data exist on health-related quality of life (HRQoL) of switching originator to biosimilar infliximab (IFX) in IBD patients. The objective of this study was to evaluate impact of switching originator to biosimilar IFX on HRQoL, disease activity, and health care costs in IBD maintenance treatment.In this single-center prospective observational study, all IBD patients receiving maintenance IFX therapy were switched to biosimilar IFX. HRQoL was measured using the generic 15D health-related quality of life instrument (15D) utility measurement and the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ). Crohn Disease Activity Index (CDAI) or Partial Mayo Score (pMayo), and fecal calprotectin (FC) served for evaluation of disease activity. Data were collected at time of switching and 3 and 12 months after switching. Patients' characteristics, clinical background information and costs were collected from patient records and the hospital's electronic database.Fifty-four patients were included in the analysis. No statistically significant changes were observed in 15D, CDAI, pMayo, and FC during 1-year follow-up. IBDQ scores were higher (P = .018) in Crohn disease 3 months after switching than at time of switching. Costs of biosimilar IFX were one-third of costs of originator one. Total costs related to secondary health care (excluding costs of IFX), were similar before and after the onset of biosimilar IFX.HRQoL and disease activity were after switching from originator to biosimilar IFX comparable, but the costs of biosimilar IFX were only one-third of those of the originator one.

Figures

Figure 1
Figure 1
Flowchart of the patients included in the study. CD = Crohn disease, IBD = inflammatory bowel disease, IFX = infliximab, UC = ulcerative colitis.
Figure 2
Figure 2
The 15D profile in Crohn disease patients. statistically significant difference (P < .05) from the time of switching to 3 months after switching. ∗∗statistically significant difference (P < .05) from the time of switching to 12 months after switching. Paired samples t test was used to test statistical significance.
Figure 3
Figure 3
The 15D profile in ulcerative colitis and inflammatory bowel disease unclassified patients. Paired samples t test was used to test statistical significance. IBD-u = IBD-unclassified, UC = ulcerative colitis.

Similar articles

See all similar articles

References

    1. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322–37. - PubMed
    1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54. - PubMed
    1. Dignass a, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28–62. - PubMed
    1. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965–90. - PubMed
    1. Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013;5:621–3. - PMC - PubMed

Publication types

MeSH terms

Feedback